Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joaquín Calaf

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Medicina Clinica|December 19, 2012
[Third generation selective estrogen receptor modulators benefits beyond bone: effects on breast]Pluvio J Coronado Martín, Joaquín Calaf Alsina
Medicina Clinica|January 2, 2013
[Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action]Joaquín Calaf Alsina, Pluvio J Coronado Martín
Medicina Clinica|December 10, 2013
[The fibroid as clinical problem]Joaquín Calaf, Maria Arqué, Oriol Porta, et al.
Menopause (New York, N.Y.)|September 22, 2011
Observational study of treatment compliance in women initiating antiresorptive therapy with or without calcium and vitamin D supplements in SpainAdolfo Díez, Cristina Carbonell, Joaquín Calaf, et al.
Maturitas|October 11, 2005
Available medical choices for the management of menopauseCamil Castelo-Branco, Santiago Palacios, Joaquín Calaf, et al.
Reumatologia Clinica|November 29, 2011
[Initial treatment trends in patient with osteoporosis: use of antiresorptive agents and pharmacologic supplements (calcium and vitamin D) in clinical practice]Cristina Carbonell, Adolfo Díez, Joaquín Calaf, et al.
Journal of Clinical Medicine|August 26, 2023
Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative ReviewGabriel Fiol, Iñaki Lete, Laura Nieto, et al.
Maturitas|September 9, 2022
Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria GroupNicolás Mendoza, Isabel Ramírez, Esther de la Viuda, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Medicina Clinica|December 19, 2012
[Third generation selective estrogen receptor modulators benefits beyond bone: effects on breast]Pluvio J Coronado Martín, Joaquín Calaf Alsina
Medicina Clinica|January 2, 2013
[Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action]Joaquín Calaf Alsina, Pluvio J Coronado Martín
Medicina Clinica|December 10, 2013
[The fibroid as clinical problem]Joaquín Calaf, Maria Arqué, Oriol Porta, et al.
Menopause (New York, N.Y.)|September 22, 2011
Observational study of treatment compliance in women initiating antiresorptive therapy with or without calcium and vitamin D supplements in SpainAdolfo Díez, Cristina Carbonell, Joaquín Calaf, et al.
Maturitas|October 11, 2005
Available medical choices for the management of menopauseCamil Castelo-Branco, Santiago Palacios, Joaquín Calaf, et al.
Reumatologia Clinica|November 29, 2011
[Initial treatment trends in patient with osteoporosis: use of antiresorptive agents and pharmacologic supplements (calcium and vitamin D) in clinical practice]Cristina Carbonell, Adolfo Díez, Joaquín Calaf, et al.
Journal of Clinical Medicine|August 26, 2023
Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative ReviewGabriel Fiol, Iñaki Lete, Laura Nieto, et al.
Maturitas|September 9, 2022
Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria GroupNicolás Mendoza, Isabel Ramírez, Esther de la Viuda, et al.
Pageof 1